{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["67(5)"],"submitter":["Bertrand J"],"pubmed_abstract":["Tenofovir (TFV) and emtricitabine (FTC) are part of the recommended highly active antiretroviral therapy (ART). Both molecules show a large interindividual pharmacokinetic (PK) variability. Here, we modeled the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV diphosphate [TFV-DP] and FTC triphosphate [FTC-TP]) collected after 4 and 24 weeks of treatment in 34 patients from the ANRS 134-COPHAR 3 trial. These patients received daily (QD) atazanavir (300 mg), ritonavir (100 mg), and a fixed-dose combination of coformulated TFV disoproxil fumarate (300 mg) and FTC (200 mg). Dosing history was collected using a medication event monitoring system. A three-compartment model with absorption delay (<i>T</i><sub>lag</sub>) was selected to describe the PK of, respectively"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["e0233918"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10190280"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records."],"pmcid":["PMC10190280"],"pubmed_authors":["Pruvost A","Fayette L","Verstuyft C","Barrail-Tran A","Taburet AM","Mentre F","Goujard C","Teicher E","Bertrand J","Savic R","Barau C"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.","description":"Tenofovir (TFV) and emtricitabine (FTC) are part of the recommended highly active antiretroviral therapy (ART). Both molecules show a large interindividual pharmacokinetic (PK) variability. Here, we modeled the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV diphosphate [TFV-DP] and FTC triphosphate [FTC-TP]) collected after 4 and 24 weeks of treatment in 34 patients from the ANRS 134-COPHAR 3 trial. These patients received daily (QD) atazanavir (300 mg), ritonavir (100 mg), and a fixed-dose combination of coformulated TFV disoproxil fumarate (300 mg) and FTC (200 mg). Dosing history was collected using a medication event monitoring system. A three-compartment model with absorption delay (<i>T</i><sub>lag</sub>) was selected to describe the PK of, respectively","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-06-12T05:52:46.029Z","creation":"2026-06-12T03:08:26.332Z"},"accession":"S-EPMC10190280","cross_references":{"pubmed":["37098914"],"doi":["10.1128/aac.02339-18"]}}